Core Viewpoint - Maiwei Biotech's stock has shown significant volatility, with a year-to-date increase of 124.41%, but a recent decline in the last five and twenty trading days [1] Group 1: Stock Performance - As of October 15, Maiwei Biotech's stock price was 45.33 CNY per share, with a market capitalization of 18.114 billion CNY [1] - The stock experienced a 2.05% increase during intraday trading, with a trading volume of 1.10 million CNY and a turnover rate of 1.20% [1] - Year-to-date, the stock has risen by 124.41%, but it has decreased by 7.72% in the last five trading days and 9.74% in the last twenty trading days [1] - Over the last sixty days, the stock has increased by 46.94% [1] Group 2: Financial Performance - For the first half of 2025, Maiwei Biotech reported revenue of 101 million CNY, a year-on-year decrease of 12.43% [2] - The company recorded a net loss attributable to shareholders of 551 million CNY, which is a 23.90% decrease compared to the previous period [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased to 17,900, up by 11.66% from the previous period [2] - The average number of circulating shares per shareholder decreased by 10.44% to 11,379 shares [2] - Notable new shareholders include Hong Kong Central Clearing Limited and Xingquan Helun Mixed A, holding 4.7426 million shares and 3.39 million shares respectively [2]

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., announced the presentation of clinical research data for its antibody-drug conjugate 7MW3711 at the 2025 European Society for Medical Oncology (ESMO) conference, highlighting its potential in treating advanced solid tumors with promising efficacy and safety profiles [1][2][3]. Group 1: Drug Overview - 7MW3711 is an antibody-drug conjugate targeting B7-H3, designed for advanced malignant solid tumors, with B7-H3 being overexpressed in many cancer types but low in normal tissues [2][3]. - The drug exhibits structural stability, high purity, and ease of industrial scaling, utilizing a novel camptothecin-based toxin that shows superior anti-tumor activity compared to similar drugs [3][4]. - The clinical trial data presented at ESMO indicates that among 54 evaluable patients receiving a dose of 4.0 mg/kg or higher, 19 patients achieved partial or complete responses [1][4]. Group 2: Clinical Trial Results - As of September 15, 2025, a total of 74 patients were enrolled in the I/II phase clinical study, with no dose-limiting toxicities observed and the maximum tolerated dose not yet reached [3][4]. - In the 4.0 mg/kg or higher dose group, the objective response rate (ORR) for esophageal cancer patients was 42.9%, with a disease control rate (DCR) of 100% [1][4]. - For lung cancer patients in the same dose group, the ORR for small cell lung cancer (SCLC) and squamous non-small cell lung cancer (Sq-NSCLC) was 50.0% and 38.5%, respectively, with DCRs of 90.0% and 92.3% [1][4].

Group 1 - The core point of the article is that Maiwei Biotech has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911 [2] Group 2 - The approval signifies a significant step forward for the company's research and development efforts in the pharmaceutical sector [2] - The clinical trial approval is expected to enhance the company's position in the competitive biotech industry [2] - This development may lead to potential future revenue streams if the clinical trials are successful [2]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911, marking a significant advancement in its drug development pipeline [1] Group 1: Drug Development - The clinical trial approval pertains to 7MW4911, which features a highly engineered design integrating three core components: a CDH17 high-specificity monoclonal antibody Mab0727, a novel cleavable linker, and a proprietary DNA topoisomerase I inhibitor MF-6 [1] - The drug is designed to overcome multi-drug resistance mechanisms, enhancing its potential effectiveness in cancer treatment [1] Group 2: Mechanism of Action - MF-6 is noted for its excellent plasma stability, controllable drug release, and strong bystander effect, which significantly enhances its anti-tumor activity [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its innovative antibody-drug conjugate (ADC) 7MW4911, targeting CDH17, a promising therapeutic target in various gastrointestinal cancers [1] Group 1: Company Developments - The clinical trial approval for 7MW4911 marks a significant milestone for the company, showcasing its capabilities in developing novel therapeutics based on its proprietary IDDC™ antibody conjugation technology platform [1] - 7MW4911 specifically targets calcium adhesion protein 17 (CDH17), which is overexpressed in colorectal cancer, gastric cancer, and pancreatic cancer, indicating its potential for precision intervention in these malignancies [1] Group 2: Industry Context - CDH17 has been validated as a potential therapeutic target through multi-omics studies across various cancer types, highlighting its relevance in the oncology landscape [1] - The abnormal high expression of CDH17 is closely associated with tumor invasion, metastasis, and poor prognosis, making it an ideal target for therapeutic intervention in gastrointestinal malignancies [1]

Core Viewpoint - The announcement indicates that Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its innovative antibody-drug conjugate (ADC) 7MW4911, targeting CDH17, a promising therapeutic target in various cancers [1] Company Summary - Maiwei Biotech has developed 7MW4911 based on its proprietary IDDC antibody conjugation technology platform [1] - The ADC targets calcium adhesion protein 17 (CDH17), which is significantly overexpressed in colorectal cancer, gastric cancer, and pancreatic cancer, making it an ideal target for precise intervention [1] Industry Summary - CDH17 has been validated as a potential therapeutic target through multi-omics studies across various cancer types, indicating its relevance in cancer treatment [1] - The abnormal high expression of CDH17 is closely associated with tumor invasion, metastasis, and poor prognosis, highlighting its importance in oncology [1]

Group 1 - The core point of the article is that Maiwei Biotech has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911 [1] - Maiwei Biotech's revenue composition for the year 2024 is projected to be 99.92% from the pharmaceutical manufacturing industry and 0.08% from other businesses [1] - As of the report, Maiwei Biotech has a market capitalization of 17.7 billion yuan [1]

Core Viewpoint - Maiwei Biotech (688062) has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911 for advanced solid tumors [1] Group 1 - The company announced the receipt of the clinical trial approval notice on October 13 [1] - The approval allows the company to proceed with clinical trials for 7MW4911, which targets advanced solid tumors [1]

证券代码：688062 证券简称：迈威生物 公告编号：2025-060 迈威（上海）生物科技股份有限公司 自愿披露关于7MW3711在2025年欧洲肿瘤内科学会 （ESMO）以海报形式报告数据及最新进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"） 靶向 B7-H3 的抗体偶联新药 7MW3711 将在 2025 年欧洲肿瘤内科学会（ESMO） 大会中以海报形式报告在晚期实体瘤患者中的 I/II 期临床研究数据及最新进展： 截至 2025 年 9 月 15 日，在 4.0mg/kg 或以上剂量组的 54 例可肿评患者中，共有 19 例患者达到部分缓解（PR）或完全缓解（CR）。在 4.0mg/kg 或以上剂量组 的 7 例可肿评食管癌（EC）患者中，ORR 为 42.9%，DCR 为 100.0%。在 4.0mg/kg 剂量组（每 2 周给药 1 次）的可肿评肺癌患者中，10 例小细胞肺癌（SCLC）和 13 例肺鳞癌（Sq-N ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-059 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公 司"）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射 用 7MW4911 的临床试验获得批准。由于药品的研发周期长、审批环节多，容易 受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 一、药品基本情况 药品名称：注射用 7MW4911 申请事项：境内生产药品注册临床试验 申请人：迈威（上海）生物科技股份有限公司 临床试验通知书编号：2025LP02657 迈威（上海）生物科技股份有限公司 自愿披露关于注射用 7MW4911 临床试验申请 获得国家药品监督管理局批准的公告 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 7 月 31 日受理的注射用 7MW4911 临床试验申请符合药品注册的有关要求， 同意本品开展晚期实体瘤的临床试验 ...